Specialty and vaccines drive earnings

Company
30 Oct 2024
5 Min read 
  • GSK Pharma's 2QFY25 performance overview and financial estimates
  •  Revenue and EBITDA growth projections for FY25-FY27
  •  Shareholding pattern and current market price
  •  Management's commentary on new launches and growth strategies
  •  Financial ratios and valuation metrics
  •  Operating leverage and margin improvement in 2QFY25
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority